![](/img/cover-not-exists.png)
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view
P. NEVEN, R. PARIDAENS, F. AMANT, H. WILDIERS, P. BERTELOOT, K. LEUNEN, A. SMEETS, C. WELTENS, W. Van Den BOGAERT, E. Van LIMBERGEN, M.R. CHRISTIAENS, I. VERGOTEVolume:
16
Year:
2006
Language:
english
Pages:
6
DOI:
10.1111/j.1525-1438.2006.00682.x
File:
PDF, 83 KB
english, 2006